cdmo.directory
← Compare landing

Richter BioLogics vs WuXi Vaccines

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/richterbiologics/wuxivaccines

CategoryRichter BioLogicsWuXi Vaccines
Listed sitecdmocdmo
SummaryGermany-based CDMO specializing in GMP-compliant microbial production of recombinant proteins, peptides, plasmid DNA, and bacterial vaccines with bioreactor capacity up to 1,500 litres and regulatory clearance from FDA, EMA, ANVISA, PMDA, and MFDS.Global CDMO specializing in end-to-end vaccine and prophylactic antibody development and manufacturing across mammalian, viral, and microbial platforms with GMP-certified facilities and over 550 million doses delivered.
Services
  • Process Development
  • Upstream Processing
  • Downstream Processing
  • CMC Analytical Development
  • Quality Control Testing
  • Recombinant Protein Manufacturing
  • Peptide Manufacturing
  • Vaccine Manufacturing
  • Microbial Fermentation
  • Vaccine Manufacturing
  • Cell-Line Development
  • Upstream Processing
  • Downstream Processing
  • Formulation Development
  • Process Development
  • CMC Analytical Development
  • Quality Control Testing
  • Recombinant Protein Manufacturing
  • Monoclonal Antibody (mAb) Manufacturing
  • Biologics Development & Manufacturing
Modalities
  • Biologics (Other)
  • Vaccine
  • Peptide
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • mRNA
  • Vaccine
IndicationsData not yet provided.
  • Infectious Disease
Locations
  • Headquarters / Development & Manufacturing, Germany, Germany
  • Headquarters, Suzhou, Jiangsu, China
Certifications
  • FDA · Identifier: FDA inspection - zero findings
  • EMA · Identifier: EMA verified
  • ANVISA · Identifier: ANVISA verified
  • PMDA · Identifier: PMDA verified
Data not yet provided.
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.